来那度胺、硼替佐米和地塞米松诱导治疗新诊断多发性骨髓瘤的实用综述
本综述讨论来那度胺、硼替佐米联合地塞米松(RVD)作为新诊断多发性骨髓瘤诱导治疗的理由,并为优化疗效、减少毒性提供处方指导。文章还强调在RVD backbone基础上加用单克隆抗体以加深缓解并提供更长久疾病控制的证据日益增多。
要点
- 多数新诊断多发性骨髓瘤患者当前标准治疗包含免疫调节剂和蛋白酶体抑制剂,最常用RVD方案并维持治疗至进展。
- 历史上美国以外地区RVD诱导治疗可及性有限,但目前全球可及性正在增加。
- 本综述为RVD诱导治疗提供处方指导,以优化疗效并最小化毒性。
核心结论
- 优化诱导治疗对于提供更长期疾病控制至关重要,当前多数患者的标准治疗包含免疫调节剂和蛋白酶体抑制剂,最常用RVD方案并维持治疗至进展。
研究设计与样本
- 本文为实用综述,讨论RVD作为诱导治疗的理由并为处方该方案提供指导以优化疗效、减少毒性。
主要发现
- 几乎所有患者会在诱导治疗后复发,因此优化诱导治疗对更长期疾病控制至关重要。
- 历史上美国以外地区RVD诱导策略可及性有限,但全球可及性正在增加。
- 在RVD backbone基础上加用单克隆抗体的证据日益增多,以加深缓解并可能提供更长久疾病控制。
临床怎么用
- 本综述为处方RVD诱导治疗提供指导,以优化疗效并最小化治疗毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For patients with newly diagnosed multiple myeloma, survival outcomes continue to improve significantly: however, nearly all patients will relapse following induction treatment. Optimisation of induction therapy is essential to provide longer term disease control and the current standard of care for most patients incorporates an immunomodulatory agent and proteasome inhibitor, most commonly lenalidomide and bortezomib in combination with dexamethasone (RVD), with maintenance until progression. Historically there has been limited access to RVD as an induction strategy outside of the United States; fortunately, there is now increasing access worldwide. This review discusses the rationale for use of RVD as induction therapy and aims to provide guidance in prescribing this regimen in order to optimise efficacy while minimising the toxicities of treatment. We also highlight the increasing evidence for the utility of addition of a monoclonal antibody to the RVD backbone to deepen responses and potentially provide longer disease control.
引用
- McCaughan GJ, Gandolfi S, Moore JJ, et al. Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. Br J Haematol. 2022. PMID: 35796524. doi:10.1111/bjh.18295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。